Solid reports positive clinical trial data

Solid Biosciences has shared positive clinical data for the first three patients in its Inspire Duchenne clinical trial. They have been dosed with Solid’s next generation gene therapy, known as SGT-003. Biopsy data at day 90 showed average microdystophin...

NICE approves DRF-funded treatment for Duchenne

New medicine for Duchenne muscular dystrophy, funded by Duchenne Research Fund and patient groups, becomes first approved treatment in the UK for all patients with Duchenne The National Institute for Health and Care Excellence (NICE) has approved vamorolone for use on...

John Walton Muscular Dystrophy Research Centre marks 10 years

We were invited to join the celebrations for the John Walton Muscular Dystrophy Research Centre’s 10th anniversary in Newcastle. The late Lord John Walton was a pioneering neurologist who made an enormous impact on muscular dystrophy diagnosis and treatment. The...

Solid expands gene therapy trial

We are pleased to share that Solid Biosciences has seen encouraging early results so far in the clinical trial of its next-generation gene therapy, SGT-003. The study, called Inspire Duchenne, began earlier this year at two sites in the US, and has already expanded to...

Solid begins dosing next-generation gene therapy

We are pleased to share that Solid Biosciences has begun dosing patients in the Phase I/II clinical study of its next-generation gene therapy, SGT-003. The study, INSPIRE DUCHENNE, is ongoing at two sites in the US – Nationwide Children’s Hospital in Columbus, Ohio,...

FDA expands approval for gene therapy Elevidys

The US Food and Drug Adminisatration has announced it has expanded the approval of Sarepta Therapeutics’ gene therapy, known as Elevidys, for the treatment of ambulatory and non-ambulatory people with Duchenne aged 4 and over. In June last year we shared that...

Pfizer provides update on gene therapy trial

Pfizer has announced that its mini-dystrophin gene therapy has not met its primary or secondary endpoints. Click here to read Pfizer’s update on Phase 3 of CIFFREO, a randomised double-blind placebo-controlled study in ambulatory boys aged 4-7. The primary...

Vamorolone approved in the UK

The Duchenne Reserach Fund is delighted to share that the MHRA (Medicines and Healthcare products Regulatory Agency) has approved vamorolone (sold under the brand name AGAMREE) for the treatment of Duchenne in patients aged 4 years and older. This is a significant...

Vamorolone approved in the EU

The European Medicines Agency (EMA) has granted marketing authorisation for vamorolone (sold under the brand name AGAMREE) for the treatment of Duchenne in patients aged 4 years and older. It is approved for all people with Duchenne, irrespective of their underlying...

Sarepta announces gene therapy results

Pharmaceutical company Sarepta has announced results of Part 1 of its Phase 3 Embark gene therapy trial for Duchenne. The trial did not meet its primary endpoint: showing a difference in a change on the North Star Ambulatory Assessment (NSAA) total score – which...